Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (151-160 of 222) with videos related to

Pageof 23
Sort By:
Plos One|March 23, 2011
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesisCatherine Emmanuel, Natalie Gava, Catherine Kennedy, et al.
Molecular Cancer Research : MCR|November 18, 2008
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumorsMichael S Anglesio, Jeremy M Arnold, Joshy George, et al.
The American Journal of Surgical Pathology|April 1, 2011
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerErin R King, Celestine S Tung, Yvonne T M Tsang, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Genes & Development|March 1, 2017
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsStephanie A Yazinski, Valentine Comaills, Rémi Buisson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2013
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerTarrik M Zaid, Tsz-Lun Yeung, Melissa S Thompson, et al.
Cancers|March 13, 2024
Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics AnalysesSammy Ferri-Borgogno, Jared K Burks, Erin H Seeley, et al.
Cancer|November 11, 2011
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group StudyDiane C Bodurka, Michael T Deavers, Chunqiao Tian, et al.
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Pageof 23

Showing results (151-160 of 222) with videos related to

Sort By:
Pageof 23
Plos One|March 23, 2011
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesisCatherine Emmanuel, Natalie Gava, Catherine Kennedy, et al.
Molecular Cancer Research : MCR|November 18, 2008
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumorsMichael S Anglesio, Jeremy M Arnold, Joshy George, et al.
The American Journal of Surgical Pathology|April 1, 2011
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerErin R King, Celestine S Tung, Yvonne T M Tsang, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Genes & Development|March 1, 2017
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsStephanie A Yazinski, Valentine Comaills, Rémi Buisson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2013
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerTarrik M Zaid, Tsz-Lun Yeung, Melissa S Thompson, et al.
Cancers|March 13, 2024
Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics AnalysesSammy Ferri-Borgogno, Jared K Burks, Erin H Seeley, et al.
Cancer|November 11, 2011
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group StudyDiane C Bodurka, Michael T Deavers, Chunqiao Tian, et al.
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Pageof 23